7/24/2019 AMR Presentation_WR SM_Final1 - Dr Khanchit
1/24
AMR Global Overview
and Action Plan
Dr Khanchit Limpakarnjanarat
WHO Representative to Indonesia
Seminar on AMR, Balai Kartini, 5 August 2015
7/24/2019 AMR Presentation_WR SM_Final1 - Dr Khanchit
2/24
World Health Organization |05-Aug-20152|
Presentation Outline
1. Global and Regional Overview
2. The Global Action Plan on AMR
3. Framework for Action on AMR4. Summary
7/24/2019 AMR Presentation_WR SM_Final1 - Dr Khanchit
3/24
World Health Organization |05-Aug-20153|
AMR..(1)
Irrational use is main driver of selection pressure thatcontributes to Antibiotic resistance:
50%antibiotics are prescribed inappropriately;
50%patients have poor compliance;
50%of populations do not have access to essentialantibiotics;
50%of antibiotics in some countries are used for
animal growth promotion;
7/24/2019 AMR Presentation_WR SM_Final1 - Dr Khanchit
4/24
World Health Organization |05-Aug-20154|
AMR..(2)
Alexander Fleming, inventor of Penicillin (18811955)
lecture.pdf-/fleming1945www.nobelprize.org/nobel_prizes/medicine/laureates/://http*
The time may come when penicillin
can be bought by anyone in the shops.
Then there is a danger that the
ignorant man may easily under dosehimself and by exposing his microbes
to non lethal quantities of the drug
make them resistant.. (Alexander
Fleming, Nobel Lecture, Dec 11,
1945)*
http://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-lecture.pdfhttp://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-lecture.pdfhttp://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-lecture.pdfhttp://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-lecture.pdfhttp://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-lecture.pdfhttp://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-lecture.pdfhttp://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-lecture.pdfhttp://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-lecture.pdfhttp://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-lecture.pdfhttp://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-lecture.pdfhttp://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-lecture.pdfhttp://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-lecture.pdfhttp://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-lecture.pdfhttp://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-lecture.pdf7/24/2019 AMR Presentation_WR SM_Final1 - Dr Khanchit
5/24
World Health Organization |05-Aug-20155|
Global and Regional Overview(1)
This (AMR) is the single greatestchallenge in infectious diseases
today.This is happening in all parts
of the world, so all countries must do
their part to tackle this global threat.
While there is a lot to be
encou raged by, much more work
needs to b e done to combat one
of the most serious global heal ththreats of our time Dr Keiji Fukuda,
WHOs ADG for Health Security
7/24/2019 AMR Presentation_WR SM_Final1 - Dr Khanchit
6/24
World Health Organization |05-Aug-20156|
Global and Regional Overview(2)
In 2013, there were estimated 480,000new cases of MDR-TB globally with
210,000 deaths. 3.5%of new and
20.5%of previously treated TB cases
are estimated to have MDR-TB. On
average, an estimated 9% of people
with MDR-TB have XDR-TB.
As of 2010, pre-treatment resistance to
HIV among adults were about 5%. Since
then, reports suggesting that pre-
treatment resistance is increasing,
peaking at 22%in some areas;
7/24/2019 AMR Presentation_WR SM_Final1 - Dr Khanchit
7/24
World Health Organization |05-Aug-20157|
Global and Regional Overview(3)
High proportions of antibiotic resistance in bacteria thatcause common infections (e.g. urinary tract infections,
pneumonia, bloodstream infections);
A high percentage of hospital-acquired infections are
caused by highly resistant bacteria such as methicillin-
resistant Staphylococcus aureus(MRSA) or multidrug-
resistant Gram-negative bacteria.
7/24/2019 AMR Presentation_WR SM_Final1 - Dr Khanchit
8/24
World Health Organization |05-Aug-20158|
Global and Regional Overview(4)
7/24/2019 AMR Presentation_WR SM_Final1 - Dr Khanchit
9/24
World Health Organization |05-Aug-20159|
Invention of New Antibiotics
Will it be the End of the Road?
Golden Era of
Antibiotics Invention
Only few new ABs
were invented
7/24/2019 AMR Presentation_WR SM_Final1 - Dr Khanchit
10/24
World Health Organization |05-Aug-201510|
Global and Regional Overview(6)
WHO report on Worldwide countrysituation analysis (April 15) focusing to
country progress on: Comprehensive, financed national plan with
accountability and civil society engagement.
Surveillance and laboratory capacity; Access to essential medicines of assured
quality;
Regulation and promotion of rational use of
medicines, and ensure proper patient care;
Infection prevention and control; Innovation, research and new tools.
7/24/2019 AMR Presentation_WR SM_Final1 - Dr Khanchit
11/24
World Health Organization |05-Aug-201511|
WHO Report 2015
Countries Involved in the Analysis
1&ua=1_eng.pdf?ua=9789241564946/1/163468/10665apps.who.int/iris/bitstream/http://
http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf?ua=1&ua=1http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf?ua=1&ua=1http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf?ua=1&ua=1http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf?ua=1&ua=1http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf?ua=1&ua=1http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf?ua=1&ua=1http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf?ua=1&ua=1http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf?ua=1&ua=1http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf?ua=1&ua=1http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf?ua=1&ua=1http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf?ua=1&ua=1http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf?ua=1&ua=1http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf?ua=1&ua=1http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf?ua=1&ua=1http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf?ua=1&ua=1http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf?ua=1&ua=1http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf?ua=1&ua=1http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf?ua=1&ua=1http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf?ua=1&ua=1http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf?ua=1&ua=1http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf?ua=1&ua=1http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf?ua=1&ua=1http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf?ua=1&ua=1http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf?ua=1&ua=1http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf?ua=1&ua=1http://apps.who.int/iris/bitstream/10665/163468/1/9789241564946_eng.pdf?ua=1&ua=17/24/2019 AMR Presentation_WR SM_Final1 - Dr Khanchit
12/24
World Health Organization |05-Aug-201512|
WHO Report 2015
(i) Countries with Financed National Plan
45%
7/24/2019 AMR Presentation_WR SM_Final1 - Dr Khanchit
13/24
World Health Organization |05-Aug-201513|
WHO Report 2015
(ii) Countries with Surveillance and Lab Capacity.(1)
No and % of Member States that had conducted AMR surveillance
7/24/2019 AMR Presentation_WR SM_Final1 - Dr Khanchit
14/24
World Health Organization |05-Aug-201514|
WHO Report 2015
(ii) Countries with Surveillance and Lab Capacity.(2)
Member States
which developed
reports on
surveillance for
antimicrobial
resistance (in the
past 5 years)
36%
7/24/2019 AMR Presentation_WR SM_Final1 - Dr Khanchit
15/24
World Health Organization |05-Aug-201515|
WHO Report 2015(iii) Access to Quality-assured Antimicrobial Medicines(1)
Countries with National Regulatory Authority
81.8%
54.5%
63.6%
7/24/2019 AMR Presentation_WR SM_Final1 - Dr Khanchit
16/24
World Health Organization |05-Aug-201516|
WHO Report 2015(iii) Access to Quality-assured Antimicrobial Medicines(2)
No and % of Member States that had a list of essential medicines
7/24/2019 AMR Presentation_WR SM_Final1 - Dr Khanchit
17/24
World Health Organization |05-Aug-201517|
WHO Report 2015
(iv) Use of Antimicrobial Medicines
%
%
%
%
7/24/2019 AMR Presentation_WR SM_Final1 - Dr Khanchit
18/24
World Health Organization |05-Aug-201518|
WHO Report 2015
(v) Promotion of Public Awaraness on AMR
No. and % of Member States that had conducted a campaign about
use of antimicrobial medicines in the previous 2 years
45.4%
7/24/2019 AMR Presentation_WR SM_Final1 - Dr Khanchit
19/24
World Health Organization |05-Aug-201519|
WHO Report 2015(vi) Infection Prevention and Control Programme
63.6%81.8%
7/24/2019 AMR Presentation_WR SM_Final1 - Dr Khanchit
20/24
World Health Organization |05-Aug-201520|
The Global Action Plan on AMR(1)
Rationale:AMR (including antibiotic resistance, the most
urgent drug resistance trend) is occurring everywhere in
the world, compromising the ability to treat infectious
diseases.
Goal: to ensure, for as long as possible, continuity of
successful treatment and prevention of infectious diseases
with effective and safe medicines that are quality-assured,
used in a responsible way, and accessible to all who need
them.
Has been endorsed at 68thWHA (2015)
7/24/2019 AMR Presentation_WR SM_Final1 - Dr Khanchit
21/24
World Health Organization |05-Aug-201521|
The Global Action Plan on AMR(4)
The five strategic objectives :
1. Improve awareness and understanding of AMR
(OneHealth);
2. Strengthen the knowledge and evidence base through
surveillance and research (human and animal);
3. Reduce the incidence of infection (IPC);
4. Optimize the use of antimicrobial agents (action plan);
and
5. Develop the economic case for sustainable investmentin new medicines, diagnostic tools, vaccines and other
interventions (med, diagnosis, vaccine).
7/24/2019 AMR Presentation_WR SM_Final1 - Dr Khanchit
22/24
World Health Organization |05-Aug-201522|
INDONESIA: Way Forward
1. Advocate to all stakeholdersAMR is a global issue;
2. Adapt the Global AMR Action Plan into a comprehensive
National AMR Action Plan;
3. Develop necessary policies and regulations to support the
implementation of National AMR Action Plan;
4. Resource mobilization to adequately finance the National
AMR Action Plan;
5. Actively engage all relevant ministries and bodies within the
government, private institutions, International agencies,
Professional Organizations, NGOs, CSOs and wider-community to implement the National Action Plan.
7/24/2019 AMR Presentation_WR SM_Final1 - Dr Khanchit
23/24
World Health Organization |05-Aug-201523|
Summary
AMR is a serious threat to global public health;
AMR is caused natural phenomenon that is propagated by
several factors that can be prevented;
AMR threatens the prevention and treatment of infections that
may lead to higher morbidity, mortality and economic loss;
AMR - The Global Action Plan is reference to develop
Country Action Plans involving all relevant government
sectors and society;
AMR Program M&E to measure effectiveness;
AMR can be effectively tackle by International collaboration.
7/24/2019 AMR Presentation_WR SM_Final1 - Dr Khanchit
24/24
World Health Organization |05-Aug-201524|
THANK YOU
Top Related